{
    "pmcid": "8515575",
    "qa_pairs": {
        "What are the key residues identified as hotspots for mutational escape in the SARS-CoV-2 spike protein?": [
            "E484, F486, and N501",
            "D614, P681, and T716",
            "K417, L452, and T478",
            "A570, D614, and Q677"
        ],
        "What is the potential therapeutic application of nanobody cocktails and biparatopic constructs according to the study?": [
            "Neutralizing SARS-CoV-2, including variants with common escape mutations",
            "Enhancing vaccine efficacy by boosting immune memory",
            "Reducing viral load in asymptomatic carriers",
            "Preventing transmission of the virus through mucosal immunity"
        ],
        "What is the primary benefit of using biparatopic nanobodies in the design of resilient nanobody binders?": [
            "Increased resilience to escape mutations by leveraging binding avidity and allosteric cooperativity",
            "Enhanced ability to penetrate host cells and deliver antiviral agents",
            "Improved stability in extreme environmental conditions",
            "Reduced production costs and increased scalability"
        ],
        "What method did the researchers use to assess the stability and binding affinity of spike protein-nanobody complexes?": [
            "Atomistic simulations and mutational profiling",
            "Cryo-electron microscopy and X-ray crystallography",
            "Mass spectrometry and nuclear magnetic resonance",
            "Flow cytometry and surface plasmon resonance"
        ],
        "Which nanobodies were specifically mentioned as targeting different epitopes on the SARS-CoV-2 spike protein?": [
            "Nb6, Nb20, VHH E, and VHH VE",
            "Nb1, Nb3, VHH A, and VHH B",
            "Nb10, Nb15, VHH C, and VHH D",
            "Nb5, Nb8, VHH F, and VHH G"
        ]
    }
}